AD________________

Award Number: DAMD17-99-1-9469

TITLE: Y Chromosome Aberrations in Prostate Cancer

PRINCIPAL INVESTIGATOR: Susan L. Naylor, Ph.D.

CONTRACTING ORGANIZATION: University of Texas
San Antonio, Texas 78284-7828

REPORT DATE: September 2003

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20040311 128

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)

2. REPORT DATE
September 2003

3. REPORT TYPE AND DATES COVERED
Annual (1 Sep 2002 - 31 Aug 2003)

4. TITLE AND SUBTITLE
Y Chromosome Aberrations in Prostate Cancer

5. FUNDING NUMBERS
DAMD17-99-1-9469

6. AUTHOR(S)
Susan L. Naylor, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
University of Texas
San Antonio, Texas 78284-7828

E-Mail: naylor@uthscsa.edu

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSORING / MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES
Original contains color plates: All DTIC reproductions will be in black and white.

12a. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 Words)
We hypothesize that chromosomal loss of the Y chromosome in prostate cancer is a specific tumorigenic event. Transfer of the Y chromosome by microcell mediated chromosome transfer into PC-3 cells resulted in suppression of tumor growth. However, these PC-3 hybrids containing the Y chromosome did grow in soft agar indicating a lack of correlation between in vitro and in vivo tumor growth. We have isolated clones with fragments of the Y chromosome and found suppression of tumorigenesis correlates with either the short arm of the Y or two small regions on the q arm. The data from the functional assay will be correlated with data form deletions in patient material. We have isolated a complete genomic microarray specific for the Y chromosome. These BAC (bacterial artificial chromosomes) will be used to perform array CGH (Comparative genomic hybridization) of prostate tumor samples. Successful identification of a gene on the Y chromosome will provide a marker that may aid in the diagnosis and prediction of prognosis of prostate cancer.

14. SUBJECT TERMS
Prostate cancer, Y chromosome, tumor suppressor gene

15. NUMBER OF PAGES
44

16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Unlimited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover..1

SF 298..2

Table of Contents..3

Introduction..4

Body..4-7

Key Research Accomplishments..7

Reportable Outcomes..8

Conclusions..8

References..9

Appendices..10-19

INTRODUCTION:
Loss of the Y chromosome has been noted in prostate tissue by other investigators [Hum. Pathol. 27:720(1996); Cancer Genet. Cytogent. 66:93(1993); and Cancer Res. 54:4472(1994)]. These experiments have not been able to resolve whether a specific region of the Y chromosome is deleted in prostate cancer. Chromosomal loss is a hallmark of a tumor suppressor gene. However, functional proof for a tumor suppressor gene comes from experiments using microcell transfer of a human Y chromosome with a selectable marker. Our data to date have demonstrated that insertion of the Y chromosome into the prostate cancer line PC-3 results in the suppression of tumor growth in nude mice. Our studies are designed to locate the region of the gene causing tumor suppression by the Y chromosome. We will correlate these data with data indicating loss of the Y chromosome in patient samples. The combination of the laboratory functional analysis with the analysis of the patient samples should indicate the location of a tumor suppressor gene on the Y chromosome and facilitate the cloning of this gene.

BODY:

Most of the work over the past year has been to develop a microarray of the Y chromosome and to make directed deletions of this chromosome. Because of the delays we encountered in having Spectral Genomics stamp our arrays, we have requested and obtained a year's no cost extension to finish the study.

Task 1. PCR analysis of tumor samples, Months 1-15

Patient samples

Over 300 patient samples have been collected an entered into the repository. We have isolated DNA from frozen tissue.

Y chromosome specific markers (PCR (polymerase chain reaction) assays)

We have continued to perfect a reliable panel of Y chromosome-specific markers. Currently we are using a panel of 34 markers that are assayed by PCR.

Analyze tumors with Y specific markers

After considering the problem of normal cell contamination in prostate tumors, it has become clear that PCR of samples may be difficult to interpret. Quantitative assays such as real time PCR would be an option if they were not so expensive. Consequently, we have decided to use the genomic array analysis of tissue until we can establish the critical region.

Task 2. In situ hybridization of interphase tumor cells, Months 3-15

Develop Y chromosome- specific probes for in situ

In isolating BAC clones for genomic arrays, we have identified clones that are firmly placed on the Y chromosome. We have also examined each clone for repetitive sequences as well as sequences on other chromosome. These clones are currently being evaluated as in situ hybridization probes

Task 3. Genomic DNA array, Months 1-15

Develop Y chromosome specific clones for DNA arrays

As the genome project has developed so has the availability of clones for specific chromosomes. Although we have used the clones we isolated previously, we were able to take advantage of the fact that a minimum tiling path for the Y chromosome is available. By choosing the clones that are included in this path we will have coverage of the 22.8 Mb of euchromatic DNA on the Y chromosome. Although the Y is considered to be 58.4 Mb, the rest of the sequence is repetitive DNA. Each clone from the path was subcloned. Each clone was tested with a PCR primer specific for the BAC clone. Some of the primers were for markers that had previously been mapped to the clone while others were newly derived from the sequence. Previously we had identified clones for 71 markers. Our coverage now is much better - at approximately three times the density as before. Several clones were eliminated because they contained too many repetitive sequences. Other clones were not positive for markers by PCR. A summary of all the data we have generated is in Table 1.

To produce BAC arrays, a large amount of DNA must be isolated for each clone. This process is quite laborious and has taken a great deal of time to isolate sufficient quantities of DNA to do all of our experiments.

Establish conditions for stamping arrays and hybridization

We spent quite a bit of time trying to optimize the conditions for producing arrays. The quality of our "homemade" arrays was at best spotty. Consequently, we have enlisted the help of Spectral Genomics in Houston to spot slides for us and to share their protocol for hybridization. As we have worked with them on other projects, we are certain that this approach will be more successful and faster than for us to make our own slides. Array CGH (comparative genomic hybridization) will allow us to quantitate Y chromosome sequences as well as precisely locate them on the chromosome. Unfortunately, there were extensive delays in Spectral Genomics producing our arrays. We have only recently received the arrays and are now perfecting the hybridization technique (see Figure 1) . This is why we requested a one year no cost extension for this grant.0

Task 4. Microcell transfer of Y chromosome fragments, Months 4-18

In our original experiments we transferred three independently marked Y chromosomes from the rodent background into PC-3 cells. Hybrids containing the Y chromosome were no longer capable of forming tumors in nude mice. During the course of this year we discovered that the Y chromosome was transferred from the Chinese hamster – Y chromosome hybrid, not the mouse – Y chromosome hybrid. The person who made the hybrids had left the laboratory and the assumption that he had used the mouse hybrids was made. After checking back in his records and checking the DNA, we concluded that the marked Y chromosome had been transferred from the Chinese hamster background. We tested the Chinese hamster parental line and found that it did not make tumors in nude mice. Consequently our plans to bypass PC-3 hybrids by using the rodent hybrids in searching for the smallest region were abandoned.

The second finding that changed our approach was the data on soft agar growth. Although the PC-3 hybrids did not make tumors in nude mice, they did grow well in soft

agar (Figure 2). To further test the cells, we isolated clones of PC-3 hybrids that had grown in soft agar. Three of the original PC-3 hybrids (2-2C1, 2-2C12, and 1-5BE) were grown in soft agar and then individual clones isolated. Of the 28 clones that were isolated, we injected 9 into nude mice (Figure 3). These clones still did not form tumors in nude mice with the exception of one clone. DNA marker analysis was performed to determine if the Y chromosome were still intact. Several of the clones had lost part of the Y chromosome and yet were suppressed for tumorigenesis.

Transfer of Y chromosome fragments into PC-3 cells
Two strategies are being taken to isolate fragments of the Y chromosome. One arose from our studies with soft agar clones. Several of the clones had lost pieces of the Y chromosome and were studied as described above (Table 2). Other isolates are also available for study. They will be assayed for markers and if portions of the Y are lost, they will be injected into nude mice.

The second strategy we are taking is more directed. Since our current data point to the short arm of the Y chromosome as the most likely location of this gene, we are making directed deletions of the chromosome. To do this we are using a Cre/lox system. The details of this experiment are shown in Figure 4. Basically, two plasmids are inserted at separate sites on the short arm of the Y chromosome. These plasmids each contain half of the HPRT (hypoxanthine phosphoribosyl transferase) gene. By using a transient transfection of bacterial Cre recombinase, the DNA will recombine to exclude the Y chromosome sequences in between the two plasmids and to make an intact HPRT gene. The correct recombinants containing deletions of the Y chromosome will be selected on HAT medium. These directed constructs will then be transferred into PC-3 cells and tested in functional assays. To date we have made all the constructs and are identifying the boundaries of insertion to determine whether the selectable marker inserted by homologous recombination and to determine whether the Cre/lox system worked as expected.

Isolate independent clones and assay for Y specific markers
We have accomplished this goal on our soft agar subclones. We will characterize our directed deletions in a like manner.

Perform in vitro assays for tumor growth
We have tested the clones in soft agar as explained above. We will characterize our directed deletions in a like manner.

Inject tumors into nude mice and quantitate tumor growth
Subclones that were obtained from soft agar have been injected into nude mice. We will characterize our directed deletions in a like manner.

Task 5. Candidate gene identification, Months 18-24
Isolate candidate cDNAs
We used two strategies to isolate candidates. First, we took advantage of the fact that a single tumor grew out of the line 2-6 E2. We cultured the tumor cells for further use.

Another line 2-6A3 never formed tumors in nude mice. Since they originated from the same marked Y chromosome, we decided these clones would be candidates for subtractive hybridization. We looked for clones that were expressed in 2-6A3, but not 2-6E2 and vice versa. The libraries obtained were assessed for inserts and plated into the 96 well format. The clones were hybridized with RNA from 2-6A3 and 2-6E2 to identify sequences that were differentially expressed.

Three dozen of the most promising clones were sequenced. Most of the clones corresponded to genes that were identified in GenBank, but a few were unique sequences. Many of the clones were Chinese hamster indicating that a small amount of Chinese hamster DNA had been transferred with the Y chromosome and that this DNA was different in each hybrid cell. After each clone was identified, the RNA abundance in the 2-6E2 and 2-6A3 hybrids was determined by either RT-PCR (reverse transcriptase polymerase chain reaction) or by northern blot. The results of this experiment are in Table 3. Although we obtained sequences that were differentially expressed, none of the genes isolated appear to be the gene on the Y chromosome responsible for tumor suppression.

The second method is to determine the genes that are in the fragment of the Y chromosome that suppresses tumor formation. As most of the unique sequences on the Y chromosome have been obtained, we are closely monitoring the genes on the Y. Any likely candidate will be examined further.

Task 6. Prepare manuscripts and final report, Months 20-24
We have prepared the first manuscript reporting the suppression of tumor formation of PC-3 by the Y chromosome (see appendix). We have submitted this manuscript to *Genes, Chromosomes and Cancer.* Other publications await our results from the arrays.

KEY RESEARCH ACCOMPLISHMENTS:

- In situ hybridization of the HisD gene confirmed the location of the selectable marker at the end of the p arm of the Y chromosome
- Introduction of the Y chromosome into PC-3 prostate cancer cells results in the suppression of tumor growth in nude mice
- The pTKm3 hybrids were confirmed as being Chinese hamster and 15 somatic cell hybrids containing fragments of the human Y chromosome were characterized for additional markers
- 38 microcell PC-3 hybrids identified with fragments of the Y chromosome were characterized with additional markers bringing the total to 34 markers
- Introduction of the Y chromosome into PC-3 prostate cancer cells does not change the growth of these cells in soft agar
- Subclones (28) that grow on soft agar were isolated from three of the PC-3 hybrid clones
- Nine soft agar-derived clones were injected into nude mice and only 1 of the subclones grew tumors in nude mice
- Soft agar subclones were characterized for 34 markers on the Y chromosome

- The region of the Y chromosome associated with the suppression of tumor growth has been limited to the short arm and two small regions of the long arm of the Y chromosome
- Plasmid constructs have been made for directed deletions on the p arm of the Y chromosome
- The genomic array of BAC clones for the Y chromosome has been confirmed by PCR for Y specific markers
- DNA has been isolated from 161 BAC clones in preparation for spotting onto glass slides by Spectral Genomics. Twenty one clones remain for the isolation of DNA.
- DNA has been isolated from frozen tumor samples
- Prostate tumor samples have been collected and patient data maintained in a database for >300 patients A subtractive library was constructed to identify possible candidates

REPORTABLE OUTCOMES:

- Abstract presented at the Cold Spring Harbor Meeting on Cancer Genetics and Tumor Suppressor Genes in August, 2002 by S. Vijayakumar, M. Bannerjee, D.K. Garcia, T. Bracht, J. Kagan, and S.L. Naylor (2002) Insertion of the Y Chromosome into PC-3 Cells Results in Suppression of Tumor Formation in Nude Mice. Cold Spring Harbor Meeting on Cancer Genetics and Tumor Suppressor Genes.
- Graduate student presentation of the data at the Texas Genetics Society Meeting, April, 2002 - S. Vijayakumar, M. Bannerjee, D.K. Garcia, T. Bracht, J. Kagan, and S.L. Naylor (2002) Y chromosome suppresses tumor formation in nude mice by the human prostate cancer cell line PC-3. Texas Genetics Society
- 182 BAC clones for the length of the Y chromosome euchromatic region have been isolated and verified. These verified clones are available to the community.

CONCLUSIONS:

We have shown that the introduction of the Y chromosome into PC-3 results in the suppression of tumor growth in nude mice. Surprisingly, the insertion of the Y chromosome does not inhibit growth in soft agar. By studying clones with fragments of the Y the gene responsible for suppression appears to be either on the short arm or on two small regions of the long arm. We have nearly in place all the genomic clones to make an array that will be used in aCGH (array comparative genomic hybridization) to detect deletions in prostate tumor samples. Since we have developed a complete tiling path for the Y chromosome, we expect to be able to precisely locate deletions. With BACs the resolution will be within 50 Kb. Consequently, we will be able to correlate our laboratory functional data with patient material. Our ultimate goal will be to clone the gene that codes for the tumor suppression activity.

REFERENCES:

Konig JJ, Teubel W, Romijn JC, Schroder FH, Hagemeijer A. (1996) Gain and loss of chromosomes 1, 7, 8, 10, 18, and Y in 46 prostate cancers. Hum Pathol. 1996 27:720-7.

Arps S, Rodewald A, Schmalenberger B, Carl P, Bressel M, Kastendieck H. (1993) Cytogenetic survey of 32 cancers of the prostate. Cancer Genet Cytogenet. 66:93-9.

Baretton GB, Valina C, Vogt T, Schneiderbanger K, Diebold J, Lohrs U. (1994) Interphase cytogenetic analysis of prostatic carcinomas by use of nonisotopic in situ hybridization. Cancer Res. 54:4472-80.

APPENDICES

Table 1. Characterization of BAC clones for a human genomic array of the Y chromosome
Table 2. Marker content of soft agar clones
Figure 1. Array comparative genomic hybridization
Figure 2. Soft agar growth of PC-3 hybrids
Figure 3. Tumor growth in nude mice of soft agar-selected clones
Figure 4. Strategy for producing directed deletions of the Y chromosome
Figure 5. Summary of the smallest region for the location of the tumor suppressor gene
Manuscript "Y chromosome suppresses the tumorigenicity of PC-3, a human prostate cancer cell line, in athymic nude mice"

Table 1

PCR Verification for Y Chromosome BAC Clones

Path	Accession No.	BAC Clone	Marker Tested	Result	DNA
1	AC006040.3	RP11-400O10	SRY	POSITIVE	YES
2	AC074181.1	RP11-515L2	515L2*	NEGATIVE	NO
3	AC006157.2	RP11-414C23	ZFY	POSITIVE	YES
4	AC006032.2	RP11-115E20	DXYS106	POSITIVE	YES
5	AC006152.3	RP11-4N7	DYS 395	POSITIVE	YES
6	AC011305.2	RP11-390E9	sY 721	POSITIVE	YES
7	AC009479.4	RP11-278L6	sY 870	POSITIVE	YES
8	AC019058.4	RP11-125B15	sY 872	POSITIVE	YES
9	AC024038.6	RP11-349O6	AF20109	POSITIVE	YES
10	AC012078.3	RP11-539O22	539O22*	POSITIVE	YES
11	AC010094.5	RP11-336O5	sY 703	POSITIVE	YES
12	AC010737.4	RP11-439L24	DXYS112	POSITIVE	YES
13	AC010084.3	RP11-145J12	DYS 253	POSITIVE	YES
14	AC010905.3	RP11-560B8	560B8*	POSITIVE	NO
15	AC010106.2	RP11-575J5	To streak		
16	AC024703.5	RP11-51N20	51N20*	POSITIVE	YES
17	AC012077.4	RP11-524G14	sY 876	POSITIVE	YES
18	AC010142.4	RP11-240N18	sY 875	POSITIVE	YES
19	AC019060.5	RP11-125K5	sY 1008	POSITIVE	YES
20	AC023423.5	RP11-430C23	sY 936	POSITIVE	YES
21	AC010722.2	RP11-122L9	sY 2138	POSITIVE	YES
22	AC010685.3	RP11-465A8	DYS 255	POSITIVE	YES
23	AC010129.3	RP11-59N9	sY 2141	POSITIVE	YES
24	AC012067.2	RP11-192N14	sY 2146	POSITIVE	YES
25	AC012667.2	RP11-357C22	sY 716	POSITIVE	YES
26	AC010081.4	RP11-65E7	DYS 256	POSITIVE	YES
27	AC010874.3	RP11-118K2	118K2*	POSITIVE	YES
28	AC010977.4	RP11-362J16	sY 2171	POSITIVE	YES
29	AC016681.2	RP11-62H15	sY 866	POSITIVE	YES
30	AC010140.3	RP11-218E11	sY 1011	POSITIVE	YES
31	AC006335.2	RP11-492C2	DYS 379	POSITIVE	YES
32	AC010154.3	RP11-573O23	DYS 257	POSITIVE	YES
33	AC010144.4	RP11-309M4	sY 1091	POSITIVE	YES
34	AC010728.4	RP11-258E22	258E22*	POSITIVE	YES
35	AC013412.3	RP11-507A3	507A3*	POSITIVE	N0
36	AC011297.3	RP11-115H13	DYS 266	POSITIVE	YES
37	AC012068.5	RP11-196J6	sY 2234	POSITIVE	YES
38	AC010104.3	RP11-540C18	DXS7855	POSITIVE	YES
39	AC010143.3	RP11-301O17	sY 887	POSITIVE	YES
40	AC007284.4	RP11-558K21	To streak		
41	AC007247.5	RP11-305H21	DYS 261	POSITIVE	YES
42	AC007274.3	RP11-105L10	DYS 260	POSITIVE	YES
43	AC007275.4	RP11-109F19	DYS 288	POSITIVE	YES
44	AC010678.4	RP11-108F14	DYS 54	POSITIVE	YES
45	AC010902.4	RP11-549J7	549J7*	NEGATIVE	
46	AC016749.4	RP11-504E20	SHGC-107423	POSITIVE	YES
47	AC051663.9	RP11-475P15	sY 1103	POSITIVE	YES
48	AC025731.12	RP11-48H21	48H21*	POSITIVE	YES
49	AC016991.5	RP11-17E15	17E15*	POSITIVE	YES
50	AC064829.6	RP11-375P13	sY 953	POSITIVE	YES
51	AC009491.3	RP11-418M8	DYS 231	POSITIVE	YES
52	AC007967.3	RP11-373F14	SHGC-80640	POSITIVE	YES
53	AC068719.3	RP11-403P11	sY 894	POSITIVE	YES
54	AC079126.3	CTB-45E23	REPEATS		

55	AC079125.4	RP11-1188O8	DYS 392	POSITIVE	YES
56	AC009952.4	RP11-175I4	DYS 258	POSITIVE	YES
57	AC025732.9	RP11-116J19	116J19*	POSITIVE	YES
58	AC006158.6	RP11-441G8	sY 1079	POSITIVE	YES
59	AC006156.5	RP11-344D2	DYS 398	POSITIVE	YES
60	AC025819.7	RP11-370N2	370N2*	POSITIVE	YES
61	AC017019.3	RP11-182H20	DYS 379	POSITIVE	YES
62	AC010891.2	RP11-453C1	453C1*	POSITIVE	YES
63	AC006986.3	RP11-155J5	DYS 268	POSITIVE	YES
64	AC006987.2	RP11-160K17	DYS 269	POSITIVE	YES
65	AC010970.3	RP11-108I14	sY 2267	POSITIVE	YES
66	AC069323.5	RP11-1126J10	1126J10*	NOT WORKING	
67	AC011293.5	RP11-75F5	DYS 270	POSITIVE	YES
68	AC012502.3	RP11-461H6	461H6*	POSITIVE	YES
69	AC011302.3	RP11-333E9	DYS 271	POSITIVE	YES
70	AC013735.5	RP11-558M10	558M10*	POSITIVE	NO
71	AC004772.2	CTB-144J1	To streak		
72	AC005942.2	CTC-298B15	To streak		
73	AC002992.1	203M13	RP11 LIBRARY- NEGATIVE		
74	AC004617.2	264M20	RP11 LIBRARY- NEGATIVE		
75	AC004810.1	CTB-69H8	To streak		
76	AC002531.1	486O2	RP11 LIBRARY- NEGATIVE		
77	AC004474.1	475I1	RP11 LIBRARY- NEGATIVE		
78	AC006565.4	CTC-484O7	To streak		
79	AC005820.1	CTC-494G17	To streak		
80	AC010877.3	RP11-218F6	sY 2366	POSITIVE	YES
81	AC006376.2	RP11-386L3	DYS 276	POSITIVE	YES
82	AC007004.3	RP11-521D3	521D3*	NEGATIVE	
83	AC006383.2	RP11-498H20	sY 2375	POSITIVE	YES
84	AC006371.2	RP11-304C24	DYS 277	POSITIVE	YES
85	AC006370.2	RP11-292P9	DYS 246	POSITIVE	YES
86	AC018677.3	RP11-264A13	sY 2395	POSITIVE	YES
87	AC010720.4	RP11-53K10	sY 2384	POSITIVE	YES
88	AC010723.3	RP11-139C10	DYS 227	POSITIVE	YES
89	AC019191.4	RP11-312H22	312H22*	POSITIVE	YES
90	AC010726.4	RP11-224C16	DYS 280	POSITIVE	YES
91	AC010979.3	RP11-384N21	sY 882	POSITIVE	YES
92	AC010879.2	RP11-235I1	sY 2386	POSITIVE	YES
93	AC017032.3	RP11-292E8	sY 910	POSITIVE	YES
94	AC006989.3	RP11-225B4	SHGC-83159	POSITIVE	YES
95	AC011289.4	RP11-59K8	DYS 390	POSITIVE	YES
96	AC010972.3	RP11-133D3	sY 863	POSITIVE	YES
97	AC007007.3	RP11-551F5	sY 2478	POSITIVE	YES
98	AC006998.3	RP11-458M9	DYS 282	POSITIVE	YES
99	AC006382.3	RP11-494J4	DYS 281	POSITIVE	YES
100	AC006462.3	RP11-389B19	sY 2458	POSITIVE	YES
101	AC006336.4	RP11-508K5	sY 770	POSITIVE	YES
102	AC016671.3	RP11-12J24	REPEATS		
103	AC017020.4	RP11-185K15	SHGC-60455	POSITIVE	YES
104	AC011749.2	RP11-455E3	SHGC-78944	POSITIVE	YES
105	AC053516.10	RP11-442J5	sY 2544	POSITIVE	YES
106	AC010135.3	RP11-128D13	DYS 200	POSITIVE	YES
107	AC010128.3	RP11-15H4	New primers		
108	AC011751.2	RP11-478I15	DYS 289	POSITIVE	YES
109	AC016678.4	RP11-55O11	DYS 243	POSITIVE	YES
110	AC015979.4	RP11-538M13	DYS 200	POSITIVE	YES
111	AC007034.4	RP11-99M1	SHGC-5485	POSITIVE	YES

112	AC007043.3	RP11-507E21	sY 2545	POSITIVE	YES
113	AC006999.2	RP11-462A19	DYS 201	POSITIVE	YES
114	AC007042.3	RP11-399H17	sY 2568	POSITIVE	YES
115	AC091329.3	RP11-568H21	To streak		
116	AC007972.4	RP11-537C24	DYS 202	POSITIVE	YES
117	AC015978.4	RP11-529I21	DYS 241	POSITIVE	YES
118	AC068704.4	RP11-434F12	DYS 203	POSITIVE	YES
119	AC007742.4	RP11-357E16	DYS 211	POSITIVE	YES
120	AC095381.1	GAP1623	Not BAC clone		
121	AC009976.4	RP11-509B6	DYS 241	POSITIVE	YES
122	AC095380.1	GAP1622	Not BAC clone		
123	AC024183.4	RP11-268K13	To streak		
124	AC007241.3	RP11-157F24	DYS 203	POSITIVE	NO
125	AC069130.6	RP11-468D10	DYS 241	POSITIVE	YES
126	AC073962.5	RP11-945E12	945E12*	POSITIVE	YES
127	AC068541.7	RP11-243P9	DYS 211	POSITIVE	YES
128	AC022486.4	RP11-569J3	DYS 208	POSITIVE	YES
129	AC007379.2	RP11-143C1	DYS 208	POSITIVE	YES
130	AC009235.4	RP11-392F24	DYS 212	POSITIVE	YES
131	AC007244.2	RP11-207L19	DYS 213	POSITIVE	YES
132	AC021210.4	RP11-389F23	sY 919	POSITIVE	YES
133	AC010133.4	RP11-118E9	sY 916	POSITIVE	YES
134	AC012062.4	RP11-80E19	sY 2608	POSITIVE	YES
135	AC010137.3	RP11-169D1	DYS 214	POSITIVE	YES
136	AC009977.4	RP11-576C2	sY 2615	POSITIVE	YES
137	AC010889.3	RP11-424G14	sY 971	POSITIVE	YES
138	AC010151.3	RP11-508P10	sY 969	POSITIVE	YES
139	AC009233.3	RP11-356K22	DYS 217	POSITIVE	YES
140	AC079157.3	RP11-1285C3	1285C3*	POSITIVE	YES
141	AC079261.2	RP11-1325K3	REPEATS		
142	AC079156.3	RP11-943F15	sY 1155	POSITIVE	YES
143	AC024250.6	RP11-684N2	sY 1155	POSITIVE	YES
144	AC009240.6	RP11-489O13	489O13*	POSITIVE	NO
145	AC011745.4	RP11-329C15	DYS 392	POSITIVE	YES
146	AC007678.3	RP11-256K9	DYS 219	POSITIVE	YES
147	AC009494.2	RP11-450B24	450B24*	POSITIVE	NO
148	AC026061.8	RP11-223K9	223K9*	NEGATIVE	
149	AC009489.3	RP11-339J4	sY 1013	POSITIVE	YES
150	AC007876.2	RP11-65G9	DYS 221	POSITIVE	YES
151	AC009239.3	RP11-470K20	470K20*	NEGATIVE	
152	AC010086.4	RP11-209I11	New primers		
153	AC010141.2	RP11-220O2	DYS 225	POSITIVE	YES
154	AC021107.3	RP11-178M5	DYS 258	POSITIVE	YES
155	AC078938.3	CTC-480L15	To streak		
156	AC024236.5	RP11-400I17	DYS 230	POSITIVE	YES
157	AC007322.4	RP11-553C13	DYS 400	POSITIVE	NO
158	AC007359.3	RP11-66M18	DYS 379	POSITIVE	YES
159	AC023342.3	RP11-95B23	DYS 77	POSITIVE	YES
160	AC025227.6	RP11-109G18	DYS 227	POSITIVE	YES
161	AC007320.3	RP11-477B5	DYS 77	POSITIVE	YES
162	AC008175.2	RP11-427G18	SHGC-7605	POSITIVE	YES
163	AC016694.2	RP11-123G1	123G1*	POSITIVE	YES
164	AC010080.2	RP11-5C5	sY 990	POSITIVE	YES
165	AC016911.6	RP11-473E1	473E1*	POSITIVE	YES
166	AC006366.3	RP11-86G22	DYS 235	POSITIVE	YES
167	AC010088.3	RP11-289L7	sY 2716	POSITIVE	YES
168	AC053490.2	RP11-140H23	DYS 236	POSITIVE	YES

169	AC007039.6	RP11-263A15	263A15*	POSITIVE	YES
170	AC006983.4	RP11-70G12	SHGC-1348	POSITIVE	YES
171	AC009947.2	RP11-39P20	DYS 12	POSITIVE	YES
172	AC016707.2	RP11-221K4	221K4*	POSITIVE	YES
173	AC016752.2	RP11-506M9	SHGC-9458	POSITIVE	YES
174	AC025246.6	RP11-589P14	To streak		
175	AC073649.3	RP11-823D8	New primers		
176	AC073893.4	RP11-978G18	sY 707	POSITIVE	YES
177	AC068601.8	RP11-1067I16	sY 710	POSITIVE	YES
178	AC023274.2	RP11-307L15	307L15*	POSITIVE	NO
179	AC012005.4	RP11-533E23	SHGC-104362	POSITIVE	YES
180	AC013465.4	RP11-424J12	424J12*	POSITIVE	YES
181	AC016698.3	RP11-160O2	DYS 235	POSITIVE	YES
182	AC010153.3	RP11-535I13	REPEATS		
183	AC025735.4	RP11-214M24	sY 2716	POSITIVE	YES
184	AC010089.4	RP11-290O3	sY 579	POSITIVE	YES
185	AC006982.3	RP11-26D12	SHGC-35663	POSITIVE	YES
186	AC006338.5	RP11-539D10	DYS 236	POSITIVE	YES
187	AC016728.4	RP11-363G6	DYS 235	POSITIVE	YES
188	AC006386.4	RP11-566H16	DYS 237	POSITIVE	YES
189	AC006328.5	RP11-102O5	sY 2729	POSITIVE	YES
190	AC007562.4	RP11-497C14	sY 710	POSITIVE	YES
191	AC010682.2	RP11-251M8	sY 707	POSITIVE	YES
192	AC017005.6	RP11-100J21	DYS 241	POSITIVE	YES
193	AC007965.3	RP11-245K4	SHGC-9458	POSITIVE	YES
194	AC006991.3	RP11-270H4	SHGC-1348	POSITIVE	YES
195	AC024067.4	RP11-487K20	DYS 247	POSITIVE	YES
196	AC013734.4	RP11-557B9	DYS 247	POSITIVE	YES
197	AC019099.6	RP11-428D10	sY 1072	POSITIVE	YES
198	AC073880.5	RP11-1136L22	REPEATS		
199	AC068123.5	RP11-242E13	REPEATS		
200	AC025226.4	RP11-57J19	SHGC-7991	POSITIVE	YES

* Custom-made primers

TOTAL 200

EXCLUDED 18

FINAL 182

DNA ISOLATED 161

To isolate DNA = 7
Clones to streak = 11
New primers required = 3
DNA preps remaining = 21

Table 2. Y Chromosome Markers Tested in the PC-3 Hybrids that Grew in Soft Agar

CLONES	2-2 C1 A	2-2 C1 B	2-2 C1 C	2-2 C1 D	2-2 C1 E	2-2 C1 F	2-2 C12 A	2-2 C12 C	2-2 C12 E
SRY									
DYS 252									
DYS 253									
DYS 266									
DYS 261									
DYS 260									
DYS 288									
DYS 257									
CENTROMERE									
DYS 271									
DYS 274									
DYS 276									
DYS 277									
DYS 278									
DYS 280									
DYS 390									
DYS 281									
DYS 198									
DYS 289									
DYS 200									
DYS 201									
DYS 212									
DYS 213									
DYS 215									
DYS 217									
DYS 392									
DYS 219									
DYS 221									
DYS 230									
DYS 231									
DYS 379									
SHGC7605									
DYS 378									
DYS 241									
DYS 247									

FAINT



Figure 1. Array comparative genomic hybridization of PC-3 cells. A. Hybridization of the BAC array. B. Ratio plot showing loss of Y chromosome markers.



Fig. 2. Presence of Y chromosome did not influence the anchorage-independent growth of PC-3. All PC-3 hybrids, plated 1000 cells/ dish grew well on soft agar.





Fig.3a. Human Y chromosome suppresses the tumor growth of PC-3 in nude mice. Out of 25 mice injected with PC-3 hybrids, only one mouse injected with 2-6 B E2 (n=5) formed tumor. 3b. Suppression of tumor growth by seven independent PC-3 hybrid clones (n=5).



Figure 4. Site directed deletions of the Y chromosome.

1. Two plasmids with parts of the HPRT gene are inserted at specific gene A and B
2. The resulting chromosome has both puro and neo resistance
3. Transient transfection with Cre recombinase results in the recombination of the loxP sites

Figure 5. Summary of the smallest region for the location of a tumor suppressor gene

Marker	
SRY	
DYS 252	
DYS 253	
DYS 266	
DYS 261	
DYS 260	
DYS 288	
DYS 257	
CENTROMERE	
DYS 271	
DYS 274	
DYS 276	
DYS 277	
DYS 278	
DYS 280	
DYS 390	
DYS 281	
DYS 198	
DYS 289	
DYS 200	
DYS 201	
DYS 212	
DYS 213	
DYS 215	
DYS 217	
DYS 392	
DYS 219	
DYS 221	
DYS 230	
DYS 231	
DYS 379	
SHGC7605	
DYS 378	
DYS 241	
DYS 247	

- Most of the long arm (q) excluded
- PC-3 hybrids grew in soft agar

The human Y chromosome suppresses the tumorigenicity of PC-3, a human prostate cancer cell line, in athymic nude mice.

Sapna Vijayakumar, Dawn Garcia, Chuck H. Hensel*[1], Mohua Banerjee, Todd Bracht, RuiHua Xiang, Jacob Kagan*[2] and Susan L. Naylor[3]

Department of Cellular & Structural Biology

University of Texas Health Science Center

7703 Floyd Curl Dr.

San Antonio, TX 78229-3900

***Current address: [1]Myriad Genetics, Salt Lake City, Utah**

[2]National Cancer Institute, Bethesda, Maryland

[3]To whom requests for reprints should be addressed at Department of Cellular & Structural Biology, University of Texas Health Science Center, 7703 Floyd Curl Dr., San Antonio, TX 78229-3900. Phone: (210) 567-3842, Fax: (210) 567-6781, E-mail: Naylor@uthscsa.edu

The loss of the Y chromosome is a frequent numerical chromosomal abnormality observed in human prostate cancer. In cancer, loss of specific genetic material frequently accompanies simultaneous inactivation of tumor suppressor genes (TSGs). It is not known whether the Y chromosome harbors such genes. To address the role of genes on the Y chromosome in human prostate cancer, we transferred a tagged Y chromosome into PC-3, a human prostate cancer cell line lacking a Y chromosome. A human Y chromosome was tagged with the *hisD* gene and transferred to PC-3 by microcell mediated chromosome transfer. Tumorigenicity of these PC-3 hybrids was tested *in vivo* and *in vitro* and the results were compared to the PCR analyses conducted on the PC-3 hybrids using Y chromosome specific markers. Out of 60 mice injected with 12 different PC-3 hybrids (five mice per hybrid) tumor growth was apparent in only one mouse, while tumors grew in all mice injected with the parental PC-3 cells. An *in vitro* assay showed that the Y chromosome did not suppress anchorage-independent growth of PC-3 cells. We found that addition of the Y chromosome suppressed tumor formation by PC-3 in athymic nude mice, and that this block of tumorigenesis was independent of the *in vitro* growth properties of the cells. This observation suggests the presence of a gene important for prostate tumorigenesis on the Y chromosome.

INTRODUCTION

Prostate cancer is the second leading cause of cancer death in American men (Jemal et al., 2002). To identify the chromosomal regions affected in prostate cancer several different tools like Giemsa-banding, flourescent *in situ* hybridization, comparative genomic hybridization, loss of heterozygozity and gene expression microarray analyses are commonly used. Cytogenetic studies have shown several chromosomal imbalances occurring in prostate cancer, including loss of chromosomal material from 1q (Latini et al., 2001), 5q, 6q, 7q, 8p, 10q, 13q, 16q, 17q, 18q, Xq (review Brothman et al., 1999) and Y (Konig et al., 1996). Earlier studies have shown that the Y chromosome is one of the most frequently lost chromosomes in prostate cancer. The Y chromosome was reported to be lost in 53% of 42 samples (Konig et al., 1994), 31% of 35 samples (Baretton et al., 1994) and 89% of 12 samples (Haapala et al., 2001) of prostate tumor examined. These studies on Y chromosome and other chromosomes lost in the prostate cancer imply loss of a gene whose loss of function results in cancer incidence or progression. Current evidence indicates that the Y chromosome is lost in several other cancers including leukemia (Sandberg, 1991), bladder cancer (Sauter et al., 1995), esophageal carcinoma (Hunter et al., 1993), gastric cancer (Castedo et al., 1992) and pancreatic cancer (Wallrapp et al., 2001). However, the significance of the loss of the Y chromosome in the development or progression of different types of cancer is still unknown. One study reported loss of the short arm of the Y chromosome in 35% of prostate tumor samples (Jordan et al., 2001). Because loss of the Y chromosome is common in prostate cancer cells and not in the normal stromal cells

(van Dekken and Alers, 1993), we hypothesize that loss of the Y chromosome plays a significant role in the genesis/progression of prostate cancer.

MATERIALS AND METHODS

Tagging Y chromosome

A Chinese hamster/human hybrid cell line containing the Y chromosome, GM06317 (Coriell Institute for Medical Research, New Jersey) was maintained in MEM Eagle's medium supplemented with 15% fetal calf serum. The cells were transfected with the *hisD* containing targeting vector pHTtkM3 (Farr et al., 1991) by electroporation. After transfection, the cells were grown in selective medium lacking histidine and containing 5mM histidinol (Gibco-BRL).

Detection of the Y chromosome

Fluorescence *in situ* hybridization: FISH was done as described (Padalecki et al., 2001). The probe for *hisD* was prepared as follows. A 3.2 Kb XhoI-EcoRI fragment containing *hisD* was biotin-labeled by nick translation (Gibco-BRL). Tyramide Signal Amplification (TSA)-FISH was done on Chinese hamster/human hybrids with a tagged Y chromosome following the procedure of Schriml et al., with minor modifications (Schriml et al., 1999). 4,6-diamidino-2-phenylindole was used as the counter stain. The slide was viewed using a Ziess Axioscop fluorescence microscope and the image captured using Applied Imaging's Probe Vision. After washing and denaturing, the slide was

reprobed with a Y chromosome probe (Vysis, Downers Grove, IL). PC-3 cells were probed with human Y chromosome paint.

Microcell mediated chromosome transfer

MMCT was done following the protocol described, with minor modifications (McNeill and Brown, 1980). Briefly, Chinese hamster/human hybrids with the tagged Y chromosome served as the donor and PC-3 as the recipient. The donor cells were treated with 0.06 μg/ml of colcemid for 24-48 hours. Microcells were obtained after centrifugation at 15,000 rpm for 30 minutes at 34°C in the presence of 10 μg/ml of cytochalasinB. Microcells were resuspended in 100 μg/ml of phytohemagglutinin-P (PHA) and later fused with PC-3 cells in the presence of 50% polyethylene glycol (PEG) and cultured in Dulbecco's modified Eagle's medium (DMEM)/F-12 medium. After 24-48 hours, the cells were put in selection medium DMEM/F-12 (without histidine) containing 5 mM histidinol. Following 10-14 days in culture, the resultant hybrids were tested for the presence of the Y chromosome.

Assays for tumor suppression

***In vivo* tumorigenicity assay**

2×10^6 cells were injected subcutaneously into the shoulder of five weeks old male Balb/c *nu/nu* mice. Each cell line was injected into five animals. Tumor growth was measured twice weekly and tumor volume was calculated using the formula, (length x width^2)/2. Any tumor formed in the experimental group was aseptically removed and expanded in DMEM/F-12 (nonselective) for further analysis. Those mice that did not

form tumors were monitored for three months. Prior to sacrifice, these mice were anesthetized and whole body scan was done by exposing to X-ray at 35kV for 6s (Faxitron X-ray Corporation, Buffalo Grove, IL).

***In vitro* tumorigenicity assay**

PC-3 or PC-3 hybrids containing the Y chromosome were seeded on 60mm soft agar plates (n=4) at a density of 1000 cells/plate. The soft agar plates have a base layer containing 0.4% agarose, 10% DMEM and 10% fetal bovine serum and a top layer consisting of 0.24% agarose. The cells were fed after 1-1.5 weeks and scored after two weeks using p-iodonitrotetrazolium violet as the dye and counted using the software GelExpert (Nucleotech Corporation, San Mateo, CA).

Characterization of the hybrids

All hybrids injected were assayed for the presence of 34 Y chromosome specific markers. The three prostate cancer cell lines, DU145, LnCaP and PC-3, were also simultaneously tested for these markers. Each 20 μl polymerase chain reaction (PCR) consisted of 120 ng of genomic DNA, 50 mM KCl, 10 mM Tris-HCl, pH8.3, 1.5–3.0 mM $MgCl_2$, 200 μM dNTPs, 10 ng of each primers and 0.15 U of Taq polymerase (Gene Choice, Frederick, MD). A stepdown program was used for amplification (Underhill et al., 1997). PCR products were visualized on 1.5% agarose gel by ethidium bromide staining.

RESULTS

Tagging and transferring of Y chromosome to PC-3 cells

We directly tested for the suppressive effect of the Y chromosome by first tagging the human Y chromosome with a selectable marker. A Chinese hamster/human cell hybrid, GM06317 was used as the source of the Y chromosome. We successfully targeted the histidinol (*hisD*) resistance gene to the *MIC2 locus* on Yp by homologous recombination using the vector pHTtkM3 (Fig. 1*a*). The presence of the *hisD* gene on the Y chromosome was detected by Tyramide Signal Amplification-Fluorescence *in situ* Hybridization (TSA-FISH) (Fig. 1*b*). The same metaphase was reprobed with a commercially available human chromosome paint specific for Y chromosome repetitive sequences. Several independent hamster/human cell hybrids with a tagged Y chromosome were established, and three, pHTtkM3 1-5B, pHTtkM3 2-2C and pHTtkM3 2-6B, were used in further experiments. Among the three prostate cancer cell lines tested, Y chromosome markers (Table1) were detected in DU145 and LnCaP (data not shown). As reported earlier (Bernardino et al., 1997), we also did not observe Y chromosome sequences in PC-3 cells by PCR analyses (Table 1) and by FISH (data not shown). The *hisD*-tagged Y chromosome was transferred to PC-3 cells using microcell mediated chromosome transfer (MMCT). Three independent chromosome transfer experiments were done for PC-3. From each of these experiments, 25 clones were picked randomly and expanded. A total of twelve

different PC-3 hybrids, each carrying a donor Y chromosome, were tested for tumorigenicity.

***In vivo* tumorigenicity assays**

To assess whether the Y chromosome can revert the tumorigenic phenotype of PC-3, we tested the tumorigenicity of PC-3 hybrids in Balb/c *nu/nu* mice. Twelve PC-3 hybrids were injected subcutaneously into the shoulder using $2X10^6$ cells per injection. Out of 60 mice injected, tumor growth was apparent in only one mouse. In contrast, all mice (n>5) injected with the parental PC-3 cell line developed tumors (Fig. 2). None of the mice exhibited any signs of metastasis as evident from X-ray scans (data not shown).

***In vitro* tumorigenicity assay**

In contrast to our *in vivo* results, the Y chromosome did not suppress the growth of PC-3 cells *in vitro*. Further, the presence of the Y chromosome had no effect on the doubling time of the cells. In contrast to the *in vivo* results, where the Y chromosome was able to block tumorigenicitcy, all twelve PC-3 hybrids plated at 1000 cells/ 60 mm plate, formed colonies in soft agar (Fig. 3). Indeed, clones containing the Y chromosome formed more colonies in soft agar than the parental PC-3 cell line, suggesting a positive effect of the Y chromosome on cell growth *in vitro*. Subclones isolated from the soft agar experiment were tested for their ability to form tumors *in vivo*. Only one of the nine subclones, 2-2 C12 E, consistently formed tumors (Fig. 4). A second clone, 2-2 C12 A, formed a tumor in only one mouse out of the five injected. The remaining seven clones (n=5 mice) did not form tumors. These data indicate that

the Y chromosome does not inhibit the *in vitro* tumorigenicity of PC-3 cells, even though tumor growth is inhibited *in vivo*.

Characterization of PC-3 hybrids

Since one of the PC-3 hybrids, 2-6B E2, developed a tumor, we characterized the Y chromosome sequences present in the hybrid cell line by PCR and compared the results to those from the remaining PC-3 hybrids that did not form tumors. The hybrid 2-6B E2, retained all 34 markers we tested (Table 1). The PC-3 hybrids 2-2 C1, 2-2 C2 and 2-2 C3 had deletions on Yq (Table 1) but still suppressed tumor formation *in vivo* (Fig. 1*b*). Most of the subclones isolated from the soft agar exhibited various deletions (Table 1), especially the subclones of PC-3 hybrid 2-2 C1 that had major deletions on the long arm of the Y chromosome. Despite this loss on the long arm, the tumorigenicity of PC-3 was suppressed. We conclude that these regions are not critical for the tumor suppression potential of the Y chromosome. Thus, we have narrowed down the region that harbors tumor suppression activity primarily to the short arm.

DISCUSSION

One unique feature of prostate cancer is its multifocality. Several independent genetically heterogeneous lesions can be found both within a tumor and also between tumors (Qian et al., 1995). The exact sequence of genetic events occurring during the progression of prostate cancer is not well understood. Though loss of the Y chromosome is a common numerical aberration observed in prostate cancer, the

significance of this loss has not yet been examined. Here, we have developed a model to test functionally the role of the Y chromosome in prostate cancer tumorigenicity. Of the three human prostate cancer cell lines, PC-3, DU145 and LnCaP, only PC-3 was found to be completely devoid of Y chromosome sequences. This is in agreement with previous reports on PC-3 where cytogenetic analyses have shown loss of the Y chromosome in this cell line. (Bernardino et al., 1997). Therefore, we chose PC-3 to study the effect of the addition of the Y chromosome on the tumorigenic phenotype of the prostate cancer cells. As evident from our data, addition of the Y chromosome suppressed the tumorigenicity of the parental PC-3 cells. The observation that tumor suppression was seen in 59 out of 60 mice challenged with PC-3 hybrids strongly supports the presence of a tumor suppressor gene on the Y chromosome. In a previous study using a similar approach, chromosome 10 was shown to suppress the tumorigenicity of the PC-3 cell line (Sanchez et al., 1996). The introduction of chromosome 10 into PC-3 cells restored an apoptotic pathway that is absent in the parental cell line. Addition of human chromosome 5 to PC-3 cells suppressed tumorigenicity and changes were noted in signaling mediated through α-catenin and E-cadherin (Ewing et al., 1995). Although the exact mechanisms of action are not known, human chromosomes 12 (Berube et al., 1994) and 17q (Murakami et al., 1995) have also been shown to suppress tumor formation by the prostate cancer cell line PPC-1, a derivative of PC-3. The insertion of chromosomes 2, 7, 8, 10, 11, 12 and 16 did not reduce the tumorigenicity in the Dunning rat prostate cancer model (Ichikawa et al., 2000), and chromosome 3 failed to suppress tumor formation by DU145 (Berube et al., 1994). The suppression of tumor growth observed after introduction of the Y

chromosome into PC-3 cells is most likely due to the presence of the transferred Y chromosome and not due to a random effect since not all the chromosomes have the ability to suppress the tumorigenicity of the prostate cancer cells.

The fact that the introduction of the Y chromosome into PC-3 did not reduce colony formation in soft agar suggests that different genetic mechanisms are involved in regulating *in vivo* and *in vitro* growth of the PC-3 hybrids. Lack of correlation of the anchorage-independent phenotype with the tumorigenic phenotype of cancer cells has been reported by others (Goyette et al., 1992; Murakami et al., 1995). In the soft agar assay, the efficiency of colony formation by the parental cell line PC-3 (1.3%), we observed, is comparable to what other investigators have reported for the cell line (Srikantan et al., 2002). At this time, the reason why PC-3 hybrids 2-2 C12 E and 2-2 C12 A regained their tumorigenic phenotype after subculturing in soft agar is not known. One possibility is the presence of microdeletions on the chromosome as only a sampling of the chromosome is determined by PCR analysis. Alternatively, a gene important for preventing tumor growth *in vivo* may have been inactivated by point mutation in these two cell lines. A more intensive approach to detect these deletions in the hybrids is in progress.

It is not surprising to see a drastic reversal in the tumorigenic phenotype of a cancer cell having multiple genetic changes just by replacing one/portion of an affected chromosome (Goyette et al., 1992). PC-3 contains a multitude of genetic aberrations (Aurich-Costa et al., 2001) including mutated p53 (Isaacs et al., 1991). The mechanism

of Y chromosome tumor suppression in PC-3 cells is at present unknown. The Y chromosome contains many genes whose function have not been closely examined in the context of cancer. It is also worth noting that in a deletion analysis on prostate cancer samples, loss of six genes lying between Yp11.3 and Yq12.1 (Perinchery et al., 2000) was observed. In our study, all hybrids retained the short arm of the Y chromosome. Furthermore, a study by Jordan et al. showed that loss of Yp is more frequent than Yq in prostate tumor samples (Jordan et al., 2001). However, the same group noticed normal copy number for the Y chromosome using touch preparation of tumor samples instead of paraffin-embedded sections (Tricoli, 1999). Our *in vivo* data support the presence of a tumor suppressor gene on the Y chromosome. A gene expression analysis provided clues that expression of certain Y chromosome specific genes including SRY and ZFY on the short arm are altered in prostate tumors (Dasari et al., 2001).

These published observations, taken together with our findings on the suppression of tumorigenicity by the Y chromosome, strongly suggest the presence of a gene on the Y chromosome that is involved in the development of prostate cancer. Further analysis of the hybrid cell lines we described will facilitate the identification of the gene(s) responsible for the suppression of PC-3 tumorigenesis and allow us to determine the mechanism of this suppression. Currently, we are focusing on identifying the minimal region on the short arm of Y chromosome that has the tumor suppression property.

ACKNOWLEDGEMENTS

These studies were supported by a grant from the Department of Defense (DAMD17-99-1-9469) and a grant from the Gustavus and Louise Pfeiffer Research Foundation.

REFERENCES

Aurich-Costa J, Vannier A, Gregoire E, Nowak F, and Cherif D. 2001. IPM-FISH, a new M-FISH approach using IRS-PCR painting probes: application to the analysis of seven human prostate cell lines. Genes Chromosomes Cancer 30:143-160.

Baretton GB, Valina C, Vogt T, Schneiderbanger K, Diebold J, and Lohrs U. 1994. Interphase cytogenetic analysis of prostatic carcinomas by use of nonisotopic in situ hybridization. Cancer Res 54:4472-4480.

Bernardino J, Bourgeois CA, Muleris M, Dutrillaux AM, Malfoy B, and Dutrillaux B. 1997. Characterization of chromosome changes in two human prostatic carcinoma cell lines (PC-3 and DU145) using chromosome painting and comparative genomic hybridization. Cancer Genet Cytogenet 96:123-128.

Berube NG, Speevak MD, and Chevrette M. 1994. Suppression of tumorigenicity of human prostate cancer cells by introduction of human chromosome del(12)(q13). Cancer Res 54:3077-3081.

Brothman AR, Maxwell TM, Cui J, Deubler DA, and Zhu XL. 1999. Chromosomal clues to the development of prostate tumors. Prostate 38:303-312.

Castedo S, Correia C, Gomes P, Seruca R, Soares P, Carneiro F, and Sobrinho-Simoes M. 1992. Loss of Y chromosome in gastric carcinoma. Fact or artifact? Cancer Genet Cytogenet 61:39-41.

Dasari VK, Goharderakhshan RZ, Perinchery G, Li LC, Tanaka Y, Alonzo J, and Dahiya R. 2001. Expression analysis of Y chromosome genes in human prostate cancer. J Urol 165:1335-1341.

Ewing CM, Ru N, Morton RA, Robinson JC, Wheelock MJ, Johnson KR, Barrett JC, and Isaacs WB. 1995. Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E-cadherin function. Cancer Res 55:4813-4817.

Farr C, Fantes J, Goodfellow P, and Cooke H. 1991. Functional reintroduction of human telomeres into mammalian cells. Proc Natl Acad Sci U S A 88:7006-7010.

Goyette MC, Cho K, Fasching CL, Levy DB, Kinzler KW, Paraskeva C, Vogelstein B, and Stanbridge EJ. 1992. Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol Cell Biol 12:1387-1395.

Haapala K, Rokman A, Palmberg C, Hyytinen ER, Laurila M, Tammela TL, and Koivisto PA. 2001. Chromosomal changes in locally recurrent, hormone-refractory prostate carcinomas by karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet 131:74-78.

Hunter S, Gramlich T, Abbott K, and Varma V. 1993. Y chromosome loss in esophageal carcinoma: an in situ hybridization study. Genes Chromosomes Cancer 8:172-177.

Ichikawa T, Hosoki S, Suzuki H, Akakura K, Igarashi T, Furuya Y, Oshimura M, Rinker-Schaeffer CW, Nihei N, Barrett JC, Isaacs JT, and Ito H. 2000. Mapping of metastasis suppressor genes for prostate cancer by microcell-mediated chromosome transfer. Asian J Androl 2:167-171.

Isaacs WB, Carter BS, and Ewing CM. 1991. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51:4716-4720.

Jemal A, Thomas A, Murray T, and Thun M. 2002. Cancer statistics, 2002. CA Cancer J Clin 52:23-47.

Jordan JJ, Hanlon AL, Al Saleem TI, Greenberg RE, and Tricoli JV. 2001. Loss of the short arm of the Y chromosome in human prostate carcinoma. Cancer Genet Cytogenet 124:122-126.

Konig JJ, Teubel W, Romijn JC, Schroder FH, and Hagemeijer A. 1996. Gain and loss of chromosomes 1, 7, 8, 10, 18, and Y in 46 prostate cancers. Hum Pathol 27:720-727.

Konig JJ, Teubel W, van Dongen JW, Romijn JC, Hagemeijer A, and Schroder FH. 1994. Loss and gain of chromosomes 1, 18, and Y in prostate cancer. Prostate 25:281-291.

Latini JM, Rieger-Christ KM, Wang DS, Silverman ML, Libertino JA, and Summerhayes IC. 2001. Loss of heterozygosity and microsatellite instability at chromosomal sites 1q and 10q in morphologically distinct regions of late stage prostate lesions. J Urol 166:1931-1936.

McNeill CA and Brown RL. 1980. Genetic manipulation by means of microcell-mediated transfer of normal human chromosomes into recipient mouse cells. Proc Natl Acad Sci U S A 77:5394-5398.

Murakami YS, Brothman AR, Leach RJ, and White RL. 1995. Suppression of malignant phenotype in a human prostate cancer cell line by fragments of normal chromosomal region 17q. Cancer Res 55:3389-3394.

Padalecki SS, Johnson-Pais TL, Killary AM, and Leach RJ. 2001. Chromosome 18 suppresses the tumorigenicity of prostate cancer cells. Genes Chromosomes Cancer 30:221-229.

Perinchery G, Sasaki M, Angan A, Kumar V, Carroll P, and Dahiya R. 2000. Deletion of Y-chromosome specific genes in human prostate cancer. J Urol 163:1339-1342.

Qian J, Bostwick DG, Takahashi S, Borell TJ, Herath JF, Lieber MM, and Jenkins RB. 1995. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 55:5408-5414.

Sanchez Y, Lovell M, Marin MC, Wong PE, Wolf-Ledbetter ME, McDonnell TJ, and Killary AM. 1996. Tumor suppression and apoptosis of human prostate carcinoma mediated by a genetic locus within human chromosome 10pter-q11. Proc Natl Acad Sci U S A 93:2551-2556.

Sandberg AA. 1991. Chromosome abnormalities in human cancer and leukemia. Mutat Res 247:231-240.

Sauter G, Moch H, Wagner U, Novotna H, Gasser TC, Mattarelli G, Mihatsch MJ, and Waldman FM. 1995. Y chromosome loss detected by FISH in bladder cancer. Cancer Genet Cytogenet 82:163-169.

Schriml LM, Padilla-Nash HM, Coleman A, Moen P, Nash WG, Menninger J, Jones G, Ried T, and Dean M. 1999. Tyramide signal amplification (TSA)-FISH applied to mapping PCR-labeled probes less than 1 kb in size. Biotechniques 27:608-613.

Srikantan V, Valladares M, Rhim JS, Moul JW, and Srivastava S. 2002. HEPSIN inhibits cell growth/invasion in prostate cancer cells. Cancer Res 62:6812-6816.

Tricoli JV. 1999. Y chromosome enumeration in touch preparations from 42 prostate tumors by interphase fluorescence in situ hybridization analysis. Cancer Genet Cytogenet 111:1-6.

Underhill PA, Jin L, Lin AA, Mehdi SQ, Jenkins T, Vollrath D, Davis RW, Cavalli-Sforza LL, and Oefner PJ. 1997. Detection of numerous Y chromosome biallelic polymorphisms by denaturing high-performance liquid chromatography. Genome Res 7:996-1005.

van Dekken H and Alers J. 1993. Loss of chromosome Y in prostatic cancer cells but not in stromal tissue. Cancer Genet Cytogenet 66:131-132.

Wallrapp C, Hahnel S, Boeck W, Soder A, Mincheva A, Lichter P, Leder G, Gansauge F, Sorio C, Scarpa A, and Gress TM. 2001. Loss of the Y chromosome is a frequent chromosomal imbalance in pancreatic cancer and allows differentiation to chronic pancreatitis. Int J Cancer 91:340-344.

Table I. PC-3 hybrids exhibited regional losses on the Y chromosome.

MARKERS	Distance between markers	PC-3 HYBRIDS													SOFT AGAR SUBCLONES								
		PC-3	1-5 BB	1-5 BE	1-5 BK	2-2 C1	2-2 C2	2-2 C3	2-2 C12	2-6 B A3	2-6 B B2	2-6 B C1	2-6 B D4	2-6 B E2	2-2 C1 A	2-2 C1 B	2-2 C1 C	2-2 C1 D	2-2 C1 E	2-2 C1 F	2-2 C12 A	2-2 C12 C	2-2 C12 E
SRY (Yp)	2562KB+	○	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
DYS 252	259 KB	○	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	■	●
DYS 253*	1222KB	○	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	○	●	●	●	●
DYS 266	2727KB	○	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
DYS 261*	616KB	○	●	●	●	●	●	●	■	●	●	●	●	●	●	●	●	●	●	●	●	●	●
DYS 260	161KB	○	●	●	●	●	●	●	●	●	●	●	●	●	●	●	■	■	●	●	●	●	●
DYS 288*	75KB	○	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	○	●
DYS 257	961KB	○	●	○	○	●	○	■	■	●	●	●	●	●	●	●	●	●	●	●	●	■	●
CENTROMERE																							
DYS 271	307KB	○	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
DYS 274	541KB	○	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
DYS 276	1065KB	○	●	●	●	●	●	■	●	●	●	●	●	●	●	○	○	○	○	○	●	●	●
DYS 277	183KB	○	●	●	●	●	●	●	●	●	●	●	■	●	○	○	○	○	○	○	●	●	●
DYS 278	79KB	○	●	●	●	●	●	●	●	●	●	●	●	●	○	○	○	○	○	○	■	■	●
DYS 280	676KB	○	●	●	●	●	●	●	●	●	●	●	●	●	○	○	○	○	○	○	●	●	●
DYS 390	667KB	○	●	●	●	●	○	○	●	●	●	●	●	●	○	○	○	○	○	○	●	●	○
DYS 281	479KB	○	●	●	●	○	●	●	●	●	●	●	●	●	○	●	○	○	○	○	■	○	●
DYS 198	716KB	○	●	●	■	●	●	●	●	■	■	●	●	■	○	○	○	○	○	○	●	■	●
DYS 289	350KB	○	●	●	●	●	●	●	●	●	●	●	●	●	○	○	○	○	○	○	■	■	●
DYS 200	82KB	○	●	●	●	●	●	●	●	●	●	●	■	●	○	○	○	○	○	○	●	●	●
DYS 201	353KB	○	●	●	●	●	●	●	●	●	●	●	●	●	○	○	○	○	○	○	●	●	●
DYS 212	1644KB	○	●	●	●	○	●	●	●	●	●	●	●	●	●	■	●	●	●	●	●	●	●
DYS 213	391KB	○	●	●	●	○	●	●	●	●	●	●	●	●	○	○	○	○	○	○	●	●	●
DYS 215	792KB	○	●	●	●	●	●	●	●	●	●	●	●	●	○	○	○	○	○	○	○	●	●
DYS 217	70KB	○	●	●	●	○	○	○	○	●	●	●	●	●	○	○	○	○	○	○	●	●	●
DYS 392	386KB	○	●	●	○	○	○	○	●	●	●	○	●	●	●	●	●	■	■	■	○	●	●
DYS 219	193KB	○	●	●	●	■	●	●	●	●	●	●	■	●	○	○	○	○	○	○	●	●	●
DYS 221	316KB	○	●	●	■	○	■	○	●	●	●	○	●	●	○	○	○	○	○	○	●	○	●
DYS 230	734KB	○	●	●	●	○	○	○	●	●	●	●	■	●	○	○	○	○	○	○	●	●	●
DYS 231*	100KB	○	●	●	●	●	○	○	●	●	●	●	●	●	■	○	○	○	■	■	●	●	●
DYS 379	169KB	○	●	●	●	●	●	●	●	●	●	●	●	●	●	■	○	○	○	○	●	●	●
SHGC7605	7KB	○	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
DYS 378	ND	○	●	●	●	○	●	○	●	●	■	●	●	●	○	○	○	○	○	○	○	●	■
DYS 241	1799KB	○	●	●	●	●	●	●	●	●	●	●	●	●	○	○	○	○	○	○	○	●	●
DYS 247(Yq)	2561KB	○	●	●	●	■	■	■	●	■	■	●	●	■	○	○	○	○	○	○	○	●	●

● Marker Present ■ Marker Faint ○ Marker Absent

*A very faint band was observed, possibly amplified from some other chromosome sequences as HeLA DNA shows positive for the marker.

+ Distance from the telomere. ND, not determined.

Figure Legends

Figure 1. Tagging of human Y chromosome. **A**) Y chromosome in hamster/human hybrid cell line was tagged with the bacterial gene histidinol dehydrogenase, *hisD*, using the vector pHTtkm3. The marker *hisD* was targeted to *MIC2* locus on the short arm of Y chromosome. SV2his has SV40 ori, *hisD* and SV40 IVS/polyA sequences. **B**) Chinese hamster/human hybrid cell showing the marker *hisD* (green) targeted to Y chromosome. Inset shows fluorescence *in situ* hybridization done subsequently using a Y chromosome paint (pink) on the same metaphase.

Figure 2. Human Y chromosome suppresses the tumor growth of PC-3 in nude mice. **A**) Out of 25 mice injected with PC-3 hybrids, only one mouse injected with 2-6 B E2 (n=5) formed tumor, while all five mice injected with PC-3 cells grew tumors. **B**) Suppression of tumor growth by seven independent PC-3 hybrid clones (n=5). All five mice injected with PC-3 cells grew tumors. *Growth curve for one mouse that grew a tumor out of five injected with 2-6 B E2.

Figure 3. Presence of Y chromosome did not suppress the anchorage-independent growth of PC-3. All PC-3 hybrids, plated 1000 cells/ dish grew well on soft agar. Bar indicates the standard error.

Figure 4. Soft agar subcultured PC-3 hybrids still maintained the non-tumorigenic phenotype. Only two subclones isolated from soft agar formed tumor *in vivo*. All five mice injected with 2-2 C12 E grew tumor. A tumor grew in only one mouse (n=5) injected with 2-2 C12 A. Tumor growth was not observed in mice (n=5) injected with rest of the seven subclones. * Growth curve for one mouse out of five injected with 2-2 C12A.

Figures

A



B

Figure 1

Figure 2

A



B





Figure 3



Figure 4